Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives
Authors
Keywords
-
Journal
CURRENT OPINION IN INFECTIOUS DISEASES
Volume 36, Issue 6, Pages 615-622
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-17
DOI
10.1097/qco.0000000000000984
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia
- (2023) Praveen Kumar Tirlangi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network)
- (2023) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
- (2023) Keith S Kaye et al. LANCET INFECTIOUS DISEASES
- Response to: “the impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19”
- (2023) Matteo Bassetti et al. EXPERT OPINION ON PHARMACOTHERAPY
- Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
- (2023) Dilip Dubey et al. Annals of Clinical Microbiology and Antimicrobials
- In vitro activity of cefepime-taniborbactam against carbapenemase producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain
- (2022) Marta Hernández-García et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections
- (2022) Alexander Lawandi et al. CLINICAL MICROBIOLOGY AND INFECTION
- Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales
- (2022) Stuart Shapiro ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19)
- (2022) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Intrinsic Antibacterial Activity of Xeruborbactam In Vitro : Assessing Spectrum and Mode of Action
- (2022) Dongxu Sun et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
- (2022) Keith S. Kaye et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- In vivo pharmacokinetic/pharmacodynamic evaluation of cefepime/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model
- (2022) Kamilia Abdelraouf et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- New antibiotics for Gram-negative pneumonia
- (2022) Matteo Bassetti et al. European Respiratory Review
- Activity of Cefepime in Combination with the novel ß-Lactamase inhibitor taniborbactam (VNRX-5133) against ESBL-producing isolates in in vitro checkerboard assays
- (2021) Wendy Kloezen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New antibiotics for the treatment of nonfermenting Gram-negative bacteria
- (2021) Matteo Bassetti et al. CURRENT OPINION IN INFECTIOUS DISEASES
- High pyocyanin production and non-motility of Pseudomonas aeruginosa isolates are correlated with septic shock or death in bacteremic patients
- (2021) Asmita Gupte et al. PLoS One
- Advances in Phage Therapy: Targeting the Burkholderia cepacia Complex
- (2021) Philip Lauman et al. Viruses-Basel
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
- (2021) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- Clinical exposure–response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model
- (2021) Maxwell J. Lasko et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017
- (2020) Sarah M. McLeod et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro efficacy of Imipenem-Relebactam and Cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae
- (2020) L. Tselepis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases
- (2020) Scott J. Hecker et al. JOURNAL OF MEDICINAL CHEMISTRY
- A systematic review on the impact of appropriate versus inappropriate initial antibiotic therapy on the outcomes of patients with severe bacterial infections
- (2020) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria
- (2020) Shazad Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance
- (2020) Matteo Bassetti et al. Antibiotics-Basel
- An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
- (2020) Burcu Isler et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Delay of appropriate antibiotic treatment is associated with high mortality in patients with community-onset sepsis in a Swedish setting
- (2019) Maria Andersson et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from United States and European hospitals during 2014-2015
- (2019) Ian Morrissey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study
- (2019) Alessandro Russo et al. JOURNAL OF INFECTION
- In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
- (2019) Marguerite L. Monogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres
- (2019) Zeb Khan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa
- (2019) Elias M. Mullane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
- (2019) Jodie C. Hamrick et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Murepavadin: a new antibiotic class in the pipeline
- (2018) Ignacio Martin-Loeches et al. Expert Review of Anti-Infective Therapy
- Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors
- (2018) Angelina Trifonova et al. Infectious Diseases
- In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
- (2017) Thomas F. Durand-Réville et al. Nature Microbiology
- Antibiotic resistance in Burkholderia species
- (2016) Katherine A. Rhodes et al. DRUG RESISTANCE UPDATES
- Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology
- (2015) Anaïs Potron et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
- (2009) P. D. Lister et al. CLINICAL MICROBIOLOGY REVIEWS
- Acinetobacter baumannii: Emergence of a Successful Pathogen
- (2008) A. Y. Peleg et al. CLINICAL MICROBIOLOGY REVIEWS
- Acinetobacter baumannii: a universal threat to public health?
- (2008) Helen Giamarellou et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search